Odonate Therapeutics Inc (NASDAQ:ODT) CEO Purchases $20,000,006.00 in Stock

Odonate Therapeutics Inc (NASDAQ:ODT) CEO Kevin C. Tang bought 769,231 shares of the stock in a transaction on Wednesday, June 26th. The stock was purchased at an average price of $26.00 per share, for a total transaction of $20,000,006.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

NASDAQ:ODT traded down $0.02 during mid-day trading on Friday, hitting $33.17. 121,196 shares of the company’s stock traded hands, compared to its average volume of 178,235. The firm’s 50 day moving average price is $30.53. The company has a market capitalization of $887.20 million, a price-to-earnings ratio of -9.11 and a beta of 1.68. Odonate Therapeutics Inc has a 12 month low of $11.54 and a 12 month high of $37.99.

Odonate Therapeutics (NASDAQ:ODT) last posted its quarterly earnings results on Thursday, April 25th. The company reported ($1.16) EPS for the quarter, beating the consensus estimate of ($1.24) by $0.08. On average, sell-side analysts forecast that Odonate Therapeutics Inc will post -4.59 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of the business. BNP Paribas Arbitrage SA raised its holdings in shares of Odonate Therapeutics by 1,187.5% in the 1st quarter. BNP Paribas Arbitrage SA now owns 1,442 shares of the company’s stock worth $32,000 after buying an additional 1,330 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Odonate Therapeutics by 1.5% in the 4th quarter. BlackRock Inc. now owns 344,069 shares of the company’s stock worth $4,844,000 after buying an additional 5,244 shares in the last quarter. TD Asset Management Inc. raised its holdings in shares of Odonate Therapeutics by 60.8% in the 4th quarter. TD Asset Management Inc. now owns 17,962 shares of the company’s stock worth $253,000 after buying an additional 6,793 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Odonate Therapeutics by 11.1% in the 4th quarter. Northern Trust Corp now owns 91,550 shares of the company’s stock worth $1,289,000 after buying an additional 9,125 shares in the last quarter. Finally, Menta Capital LLC acquired a new position in shares of Odonate Therapeutics in the 4th quarter worth approximately $187,000. 91.48% of the stock is owned by hedge funds and other institutional investors.

Several analysts recently weighed in on the company. Zacks Investment Research upgraded HB Fuller from a “sell” rating to a “hold” rating in a research note on Wednesday, July 3rd. Cowen restated a “buy” rating on shares of Odonate Therapeutics in a research note on Monday, June 3rd. Finally, ValuEngine downgraded Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 18th.

About Odonate Therapeutics

Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

See Also: Buy Rating

Insider Buying and Selling by Quarter for Odonate Therapeutics (NASDAQ:ODT)

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.